Payer Communications Safe Harbor Should Extend To Off-Label Uses – Industry
US FDA should apply same regulatory protections to manufacturer communications with payers about unapproved uses that agency draft guidance provides to information exchanges about investigational products, biopharma companies say.
You may also be interested in...
Final guidance on drug manufacturer communications with payors adopts industry call to include exchanges about unapproved uses; they will not be considered evidence of intended use.
Bristol, Genentech execs describe how their companies are adapting to US FDA loosening some restrictions on how sponsors can talk about data that are 'related to' approved indications.
Industry exec Jimenez hopes President Trump’s reform proposals, expected in next three months, will include measures to ensure manufacturer rebates are passed through to patients and encourage outcomes-based reimbursement contracts with payers.